Omeros Corporation

Symbol: OMER

NASDAQ

3.56

USD

Market price today

  • -1.8868

    P/E Ratio

  • 1.5094

    PEG Ratio

  • 206.28M

    MRK Cap

  • 0.00%

    DIV Yield

Omeros Corporation (OMER) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-0.31%

Return on Equity

-12.91%

Return on Capital Employed

-0.51%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Gregory A. Demopulos M.D.
Full-time employees:198
City:Seattle
Address:The Omeros Building
IPO:2009-10-08
CIK:0001285819

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Return on Investments

The company's asset efficiency, represented by a robust -0.311% return, is a testament to Omeros Corporation's adeptness in optimizing resource deployment. Omeros Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -12.907%. Furthermore, the proficiency of Omeros Corporation in capital utilization is underscored by a remarkable -0.506% return on capital employed.

Stock Prices

Omeros Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $3.48, while its low point bottomed out at $3.16. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Omeros Corporation's stock market.

Liquidity Ratios

Analyzing OMER liquidity ratios reveals its financial health of the firm. The current ratio of 408.69% gauges short-term asset coverage for liabilities. The quick ratio (392.60%) assesses immediate liquidity, while the cash ratio (13.33%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio408.69%
Quick Ratio392.60%
Cash Ratio13.33%

Profitability Ratios

The effective tax rate stands at -7.72%, revealing its tax efficiency. The net income per EBT, 73.17%, and the EBT per EBIT, 97.86%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate-7.72%
Net Income per EBT73.17%
EBT per EBIT97.86%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.09, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding393
Days of Payables Outstanding3170
Payables Turnover0.12

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 1.20, and free cash flow per share, 1.19, depict cash generation on a per-share basis. The cash per share value, 2.75, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share1.20
Free Cash Flow per Share1.19
Cash per Share2.75
Free Cash Flow to Operating Cash Flow Ratio0.99
Cash Flow Coverage Ratio0.22
Short Term Coverage Ratio5.44
Capital Expenditure Coverage Ratio175.41
Dividend Paid and Capex Coverage Ratio175.41

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 90.79%, highlights its total liabilities relative to assets. With a debt-equity ratio of -13.75, we discern the balance between debt and equity financing. The long-term debt to capitalization, 108.20%, and total debt to capitalization, 107.84%, ratios shed light on its capital structure. An interest coverage of -10.96 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio90.79%
Debt Equity Ratio-13.75
Long Term Debt to Capitalization108.20%
Total Debt to Capitalization107.84%
Interest Coverage-10.96
Cash Flow to Debt Ratio0.22
Company Equity Multiplier-15.14

Per Share Data

Net income per share, -1.88, reflects the portion of profit attributed to each share. The book value per share, -0.40, represents the net asset value distributed per share, while the tangible book value per share, -0.40, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-1.88
Book Value Per Share-0.40
Tangible Book Value Per Share-0.40
Shareholders Equity Per Share-0.40
Interest Debt Per Share4.98
Capex Per Share-0.01

Growth Ratios

EBIT growth, -0.70%, and operating income growth, -0.70%, offer insights into operational profitability progression. The net income growth, -509.40%, showcases bottom-line expansion, and the EPS growth, -508.70%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth3.36%
EBIT Growth-0.70%
Operating Income Growth-0.70%
Net Income Growth-509.40%
EPS Growth-508.70%
EPS Diluted Growth-508.70%
Operating Cash Flow Growth186.41%
Free Cash Flow Growth185.80%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share214.55%
5-Year Operating CF Growth per Share155.78%
3-Year Operating CF Growth per Share168.04%
10-Year Net Income Growth per Share-34.77%
5-Year Net Income Growth per Share28.03%
3-Year Net Income Growth per Share22.23%
10-Year Shareholders Equity Growth per Share38.14%
5-Year Shareholders Equity Growth per Share-102.98%
3-Year Shareholders Equity Growth per Share97.39%
Receivables Growth-84.52%
Asset Growth-35.99%
Book Value per Share Growth-129.16%
Debt Growth5.72%
R&D Expense Growth1.91%
SGA Expenses Growth-3.81%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 559,636,272.29, captures the company's total value, considering both debt and equity. Income quality, -0.43, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value559,636,272.29
Income Quality-0.43
Capex to Operating Cash Flow-0.57%
Capex to Depreciation-46.30%
Graham Number4.10
Return on Tangible Assets-31.15%
Graham Net Net-3.24
Working Capital164,582,000
Tangible Asset Value-24,983,000
Net Current Asset Value-185,354,000
Invested Capital-14
Average Receivables139,743,500
Average Payables6,850,500
Days Payables Outstanding3060
ROIC-34.80%
ROE4.72%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -8.90, and the price to book ratio, -8.90, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, 2.78, and price to operating cash flows, 2.97, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-8.90
Price to Book Ratio-8.90
Price Cash Flow Ratio2.97
Price Earnings to Growth Ratio1.51
Enterprise Value Multiple0.95
Price Fair Value-8.90
Price to Operating Cash Flow Ratio2.97
Price to Free Cash Flows Ratio2.78
Price to Tangible Book Ratio-8.21
Enterprise Value Over EBITDA-3.42
EV to Operating Cash Flow7.49
Earnings Yield-57.43%
Free Cash Flow Yield36.22%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Omeros Corporation (OMER) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.887 in 2024.

What is the ticker symbol of Omeros Corporation stock?

The ticker symbol of Omeros Corporation stock is OMER.

What is company IPO date?

IPO date of Omeros Corporation is 2009-10-08.

What is company current share price?

Current share price is 3.560 USD.

What is stock market cap today?

The market cap of stock today is 206281352.000.

What is PEG ratio in 2024?

The current 1.509 is 1.509 in 2024.

What is the number of employees in 2024?

In 2024 the company has 198.